Literature DB >> 21045078

Diabesity: an overview of a rising epidemic.

Youssef M K Farag, Mahmoud R Gaballa.   

Abstract

'Diabesity' is the term for diabetes occurring in the context of obesity. In this review, we will overview the latest epidemiological data available describing the rising prevalence, health impact and economic impact of diabesity. We will also outline the measures required to slowdown this newly evolving epidemic. The global prevalence of diabetes in 2010 was 284 million people worldwide constituting around 6.4% of the world population, which is higher than was projected in earlier studies. Furthermore, the projections for 2030 show the prevalence to reach 439 million individuals comprising ~7.7% of the world population. The burden of diabetes on the world economy has been rising steadily in the last decade to reach $376 billion in 2010 and is expected to reach $490 billion in 2030. Diabesity represents a substantial economic burden as reflected by diabetes and obesity consuming 14 and 5.7% of the USA's total health expenditure, respectively, representing the highest known expenditure on diabesity worldwide. When costs associated with being overweight were also included, the upper limit of obesity expenditure rises to 9.1% of the USA's total healthcare expenditure. The highest recorded expenditure on diabetes alone was in Saudi Arabia consuming 21% of the country's total health expenditure, with no data available about the health expenditure on obesity. The health impact of diabesity is substantial to include long-term diabetic complications, reduction in health-related functioning, reduction of quality of life and reduced overall life expectancy. Long-term complications include myocardial infarction, cerebrovascular stroke and end-stage renal disease. Also recent advances have found that there is an association between chronic stress, depression and sleeping troubles to both diabetes and obesity. This century is the unprecedented diabetogenic era in human history. It is thus urgent to take steps including screening, prevention and early management in an attempt to control this evolving epidemic of diabesity.

Entities:  

Mesh:

Year:  2010        PMID: 21045078     DOI: 10.1093/ndt/gfq576

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  87 in total

1.  Obesity-insulin targeted genes in the 3p26-25 region in human studies and LG/J and SM/J mice.

Authors:  Aldi T Kraja; Heather A Lawson; Donna K Arnett; Ingrid B Borecki; Ulrich Broeckel; Lisa de las Fuentes; Steven C Hunt; Michael A Province; James Cheverud; D C Rao
Journal:  Metabolism       Date:  2012-03-03       Impact factor: 8.694

Review 2.  Transgenic mouse models resistant to diet-induced metabolic disease: is energy balance the key?

Authors:  Laura A A Gilliam; P Darrell Neufer
Journal:  J Pharmacol Exp Ther       Date:  2012-06-13       Impact factor: 4.030

3.  Pre-existing differences in motivation for food and sensitivity to cocaine-induced locomotion in obesity-prone rats.

Authors:  Peter J Vollbrecht; Cameron W Nobile; Aaron M Chadderdon; Emily M Jutkiewicz; Carrie R Ferrario
Journal:  Physiol Behav       Date:  2015-09-28

Review 4.  Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction.

Authors:  Matthias Barton; Oliver Baretella; Matthias R Meyer
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

Review 5.  Selecting the optimal cell for kidney regeneration: fetal, adult or reprogrammed stem cells.

Authors:  Orit Harari-Steinberg; Oren Pleniceanu; Benjamin Dekel
Journal:  Organogenesis       Date:  2011-04-01       Impact factor: 2.500

6.  Risk factors in heart disease: therapeutic interventions.

Authors:  Nilanjana Maulik; Juan A Sanchez
Journal:  Antioxid Redox Signal       Date:  2011-06-08       Impact factor: 8.401

7.  Serum Cadmium Levels and Risk of Metabolic Syndrome: A Cross-Sectional Study.

Authors:  Nour Ayoub; Hiba Mantash; Hassan R Dhaini; Abbas Mourad; Mohammad Hneino; Zeina Daher
Journal:  Biol Trace Elem Res       Date:  2021-01-06       Impact factor: 3.738

8.  Consumption of sweet beverages and type 2 diabetes incidence in European adults: results from EPIC-InterAct.

Authors:  D Romaguera; T Norat; P A Wark; A C Vergnaud; M B Schulze; G J van Woudenbergh; D Drogan; P Amiano; E Molina-Montes; M J Sánchez; B Balkau; A Barricarte; J W J Beulens; F Clavel-Chapelon; S P Crispim; G Fagherazzi; P W Franks; V A Grote; I Huybrechts; R Kaaks; T J Key; K T Khaw; P Nilsson; K Overvad; D Palli; S Panico; J R Quirós; O Rolandsson; C Sacerdote; S Sieri; N Slimani; A M W Spijkerman; A Tjonneland; M J Tormo; R Tumino; S W van den Berg; P R Wermeling; R Zamara-Ros; E J M Feskens; C Langenberg; S J Sharp; N G Forouhi; E Riboli; N J Wareham
Journal:  Diabetologia       Date:  2013-04-26       Impact factor: 10.122

Review 9.  Painful diabetic neuropathy is more than pain alone: examining the role of anxiety and depression as mediators and complicators.

Authors:  Rakesh Jain; Shailesh Jain; Charles L Raison; Vladimir Maletic
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

10.  Hyperoxia-induced cardiotoxicity and ventricular remodeling in type-II diabetes mice.

Authors:  Jennifer Leigh Rodgers; Eva Samal; Subhra Mohapatra; Siva Kumar Panguluri
Journal:  Heart Vessels       Date:  2017-12-05       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.